COVID-19 in pediatric nephrology centers in Turkey

EMRE LEVENTOĞLU
YEŞİM ÖZDEMİR ATİKEL
HÜLYA NALÇACIOĞLU
İSMAİL DURSUN
HASAN DURSUN

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/medical

Part of the Medical Sciences Commons

Recommended Citation
LEVENTOĞLU, EMRE; ATİKEL, YEŞİM ÖZDEMİR; NALÇACIOĞLU, HÜLYA; DURSUN, İSMAİL; DURSUN, HASAN; YILDIRIM, ZEYNEP NAGEHAN YÜRÜK; YILDIZ, NURDAN; AKSOY, GÜLŞAH KAYA; TAŞDEMİR, MEHMET; ÇELAKIL, MEHTAP; KILIÇ, BELTİNGE DEMİRCİOĞLU; SELÇUK, ŞENAY ZIRHLI; CANPOLAT, NUR; ÇAKICI, EVRİM KARGIN; and ÖZLÜ, SARE GÜLFEM (2022) "COVID-19 in pediatric nephrology centers in Turkey," Turkish Journal of Medical Sciences: Vol. 52: No. 6, Article 4. https://doi.org/10.55730/1300-0144-5521
Available at: https://journals.tubitak.gov.tr/medical/vol52/iss6/4

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more information, please contact academic.publications@tubitak.gov.tr.
COVID-19 in pediatric nephrology centers in Turkey

Authors
EMRE LEVENTOĞLU, YEŞİM ÖZDEMİR ATİKEL, HÜLYA NALÇACIOĞLU, İSMAİL DURSUN, HASAN DURSUN, ZEYNEP NAGEHAN YÜRÜK YILDIRIM, NURDAN YILDIZ, GÜLŞAH KAYA AKSOY, MEHMET TAŞDEMİR, MEHTAP ÇELAKIL, BELTİNGE DEMİRCİOĞLU KILIÇ, ŞENAY ZIRHLI SELÇUK, NUR CANPOLAT, EVRİM KARGIN ÇAKICI, and SARE GÜLFEM ÖZLÜ

This article is available in Turkish Journal of Medical Sciences: https://journals.tubitak.gov.tr/medical/vol52/iss6/4
COVID-19 in pediatric nephrology centers in Turkey

Emre LEVENTOĞLU1,2, Yeşim ÖZDEMİR ATIKEL3, Hülya NALÇACIOĞLU1, İsmail DURSUÑ4, Hasan DURSUÑ5, Zeynep YÜRÜK YILDIRIM1, Nurdan YILDIZ1, Gülşah KAYA AKSOY3, Mehmet TAŞDEMİR3, Mehtap ÇELAKIL1, Beltinge DEMİRCİOĞLU KILIÇ1, Şena ZIRHIL SELÇUK2, Nur CANPOLAT3, Evrim KARGIN ÇAKICI1, Sare Gülfer ÖZLÜ1, Sebahat TULPAR1, Seçilçuk YÜKSEL1, Bahriye ATMİS1, Serra SÜRLMELİ DÖVEN1, Sevgin TANER1, Pelin ERTAN1, Ash KAVAZ5, Meral TÖRÜN BAYRAM1, Mukaddes KALYONCU1, Kaan GÜLLEROĞLU1, Caner KABASAKAL3, Belde KASAP DEMİR1, Rüneya Yasemin ÇİÇEK8, İlham BİLGE9, Osman DÖNMEZ1, Ashlan KARA1, Önder YAVAŞCAN1, Gül ÖZÇELİK10, Deniz GEZİĞİN YILDIRIM2, Muhammet Akit GÜLER10, Ferah SÖNMEZ10, Hakcan POYRAZOĞLU1, Sema AKMAN4, Rezan TOPALOĞLU10, Harika ALPAY7, Sevcan A. BAKKALOĞLU10

1Departments of Pediatric Nephrology and Rheumatology, Faculty of Medicine, Gazi University, Ankara, Turkey
2Department of Pediatric Nephrology, Eskişehir City Training and Research Hospital, Eskişehir, Turkey
3Department of Pediatric Nephrology, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey
4Department of Pediatric Nephrology, Faculty of Medicine, Erciyes University, Kayseri, Turkey
5Department of Pediatric Nephrology, Prof. Dr. Cemil Taşçıoğlu City Hospital, University of Health Sciences, İstanbul, Turkey
6Department of Pediatric Nephrology, İstanbul Faculty of Medicine, İstanbul University, İstanbul, Turkey
7Department of Pediatric Nephrology, Istanbul Pendik Education and Research Hospital, Marmara University, İstanbul, Turkey
8Department of Pediatric Nephrology, Faculty of Medicine, Akdeniz University, Antalya, Turkey
9Departments of Pediatric Nephrology and Rheumatology, Faculty of Medicine, Koç University, İstanbul, Turkey
10Department of Pediatric Nephrology, Hatay State Hospital, Hatay, Turkey
11Department of Pediatric Nephrology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey
12Department of Pediatric Nephrology, Turgut Özal Medical Center, İnönü University, Malatya, Turkey
13Department of Pediatric Nephrology, Cerrahpaşa Faculty of Medicine, İstanbul University, İstanbul, Turkey
14Department of Pediatric Nephrology, Dr. Sami Ulus Maternity and Child Health and Diseases Training and Research Hospital, University of Health Sciences, Ankara, Turkey
15Department of Pediatric Nephrology, Ankara City Training and Research Hospital, Ankara, Turkey
16Department of Pediatric Nephrology, İstanbul Bakırköy Dr. Sadi Konuk Research and Training Hospital, University of Health Sciences, İstanbul, Turkey
17Department of Pediatric Nephrology, Faculty of Medicine, Pamukkale University, Denizli, Turkey
18Department of Pediatric Nephrology, Faculty of Medicine, Çukurova University, Adana, Turkey
19Department of Pediatric Nephrology, Faculty of Medicine, Mersin University, Mersin, Turkey
20Department of Pediatric Nephrology, Adana City Training and Research Hospital, University of Health Sciences, Adana, Turkey
21Department of Pediatric Nephrology, Faculty of Medicine, Celal Bayar University, Manisa, Turkey
22Department of Pediatric Nephrology, Faculty of Medicine, Osmangazi University, Eskişehir, Turkey
23Department of Pediatric Nephrology, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey
24Departments of Pediatric Nephrology and Rheumatology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey
25Department of Pediatric Nephrology, Faculty of Medicine, Başkent University, Ankara, Turkey
26Department of Pediatric Nephrology, Faculty of Medicine, Ege University, İzmir, Turkey
27Departments of Pediatric Nephrology and Rheumatology, Faculty of Medicine, İzmir Katip Celebi University, İzmir, Turkey
28Department of Pediatric Nephrology, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey
29Departments of Pediatric Nephrology and Rheumatology, Faculty of Medicine, Uludağ University, Bursa, Turkey
30Departments of Pediatric Nephrology and Rheumatology, Faculty of Medicine, Fırat University, Elazığ, Turkey
31Department of Pediatric Nephrology, Faculty of Medicine, Medipol University, İstanbul, Turkey
32Department of Pediatric Nephrology, Şişli Hamidiye Etfal Training and Research Hospital, University of Health Sciences, İstanbul, Turkey
33Department of Pediatric Nephrology, Faculty of Medicine, Atatürk University, Erzurum, Turkey
34Department of Pediatric Nephrology, Faculty of Medicine, Adnan Menderes University, Aydın, Turkey
35Department of Pediatric Nephrology, Faculty of Medicine, Hacettepe University, Ankara, Turkey

* Correspondence: dremrelevent@gmail.com

1762
Background/aim: There is limited data on COVID-19 disease in children with kidney disease. We aimed to investigate the characteristics and prognosis of COVID-19 in pediatric nephrology patients in Turkey.

Materials and methods: This was a national, multicenter, retrospective cohort study based on an online survey evaluating the data between 11th March 2020 and 11th March 2021 as an initial step of a detailed pediatric nephrology COVID-19 registry.

Results: Two hundred and three patients (89 girls and 114 boys) were diagnosed with COVID-19. One-third of these patients (36.9%) were between 10–15 years old. Half of the patients were on kidney replacement therapy: kidney transplant (KTx) recipients (n = 56, 27.5%), patients receiving chronic hemodialysis (n = 33, 16.3%) and those on peritoneal dialysis (PD) (n = 18, 8.9%). Fifty-four (26.6%) children were asymptomatic. Eighty-two (40.3%) patients were hospitalized and 23 (28%) needed intensive care unit admission. Fifty-five percent of the patients were not treated, while the remaining was given favipiravir (20.7%), steroid (16.3%), and hydroxychloroquine (11.3%). Acute kidney injury developed in 19.5% of hospitalized patients. Five (2.4%) had MIS-C. Eighty-three percent of the patients were discharged without any apparent sequelae, while 7 (3.4%) died. One hundred and eight health care staff were infected during the study period.

Conclusion: COVID-19 was most commonly seen in patients who underwent KTx and received HD. The combined immunosuppressive therapy and frequent exposure to the hospital setting may increase these patients’ susceptibility. Staff infections before vaccination era were alarming, various precautions should be taken for infection control, particularly optimal vaccination coverage.

Key words: Children, COVID-19, kidney, pediatric nephrology, Turkey

1. Introduction
Coronavirus disease 2019 (COVID-19) is a novel viral disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus, which has been declared a pandemic due to its global spread [1,2]. One year after the first confirmed case of COVID-19 in Turkey on March 11th, 2020, the total number of infected individuals reached approximately 3 million at the end of the first year [3]. The epidemiological characteristics of children infected with SARS-CoV-2 are limited; however, its incidence is much lower than in adults. Published studies in the early months of the pandemic suggest that children corresponded to less than 5% of all COVID-19 cases and were less likely to become severely ill compared to adults [4,5]. However, with the spread of new variants, the frequency of pediatric patients has increased as of May 2021. Despite excellent overall pediatric outcomes, severe and fatal cases do occur [6]. Children with severe COVID-19 are more likely to have preexisting chronic medical conditions (e.g., cardiac, respiratory, neurodevelopmental, malignancy, or immunosuppression) [4,7–10]. However, most children present clinical symptoms ranging from asymptomatic to mild/moderate illness and relatively fewer children with COVID-19 require hospitalization or admission to the intensive care unit (ICU) [11].

Several reports regarding adults have reported underlying pathologies or preexisting comorbidities as important risk factors for severe COVID-19 [12]. Chronic kidney disease (CKD) was found to be associated with the severity and mortality of COVID-19 [13,14]. Specifically, patients with CKD had a three-fold risk of developing severe COVID-19 [15]. Also, pediatric patients on dialysis are at significant risk for experiencing infectious diseases such as COVID-19 because of their compromised immune system and their frequent exposure to the hospital setting [16]. About one-third of end-stage kidney disease (ESKD) patients with dialysis who were hospitalized with COVID-19 died [17]. The high mortality rate might be associated with the diminished immune system from uremia in ESKD patients [18]. However, pediatric nephrology (PN) patients, i.e. CKD, hemodialysis (HD), and kidney transplantation (KTx) patients and those on immunosuppressive treatment were reported to have a lower risk compared to adults in limited studies [5, 19–21].

We conducted this multicenter, national collaborative study to investigate the one-year data of characteristics and prognosis of COVID-19 in pediatric nephrology patients in Turkey as an initial step of a detailed pediatric nephrology COVID-19 registry.

2. Materials and methods
2.1. Study design
This was a nationwide, multi-center, retrospective cohort study based on the data collected from children and adolescents with COVID-19 who were followed up in pediatric nephrology departments between 11th March 2020 (the day of detection of the first case in Turkey) and 11th March 2021. An online questionnaire was sent to all pediatric nephrology centers in Turkey. The centers were requested to submit all confirmed cases of COVID-19 (inpatients and outpatients) under the age of 20 years. A total of 35 pediatric nephrology centers reported their COVID-19 cases during a study period.
The online questionnaire forms included information on demographics, primary renal diagnosis as well as kidney replacement therapy modality and associated medications, comorbid conditions such as obesity, hypertension, cardiovascular diseases or growth retardation and disease presentation, diagnostic tools for COVID-19, hospital and/or intensive care unit (ICU) stay, and outcome of the COVID-19 disease course.

This study was approved by the Ethics and Clinical Research Committee of Gazi University.

2.2. Diagnostic tools for COVID-19 and definitions

COVID-19 was diagnosed by laboratory confirmation using the reverse transcriptase-polymerase chain reaction (PCR) by Bio-Speedy<sup>®</sup> SARS-CoV-2 real time PCR kit or serology tests. Also, patients with thorax tomography findings and those having highly suggestive clinical symptoms compatible with COVID-19 such as fever, cough, shortness of breath, tiredness, loss of taste and smell, headache, or myalgia were also diagnosed as COVID-19 [1]. COVID-19 disease severity, method of diagnosis, treatment, length of hospital stay, and disease outcome was documented. The severity of the disease was classified as mild, moderate, severe, or critical illness. The mild disease was defined as upper respiratory symptoms for a short duration or asymptomatic infection; moderate disease as mild pneumonia symptoms; severe disease as mild or moderate clinical features, plus any manifestations that suggest disease progression; critical illness as rapid disease progression, plus any other conditions like a respiratory failure with need for mechanical ventilation, septic shock, organ failure that needs monitoring in the intensive care unit [22].

Regarding comorbid conditions, obesity was defined as a body mass index above the 95<sup>th</sup> percentile according to the national pediatric growth percentiles [23]. Hypertension was defined as an office blood pressure greater than the 95<sup>th</sup> percentile according to age, sex, and height specific normative values in the Fourth Report [24]. The number of patients with the multisystem inflammatory syndrome (MIS-C), characterized by fever, systemic inflammation, and multiple organ involvement requiring hospitalization due to confirmed SARS-CoV-2 infection, was also reported [25]. Acute kidney injury was defined as an increase of serum creatinine by 0.3 mg/dL or 50% from baseline within 7 days, according to the Kidney Disease: Improving Global Outcomes [26].

2.3. Statistical analysis

In the presentation of descriptive statistics, the categorical data were expressed as numbers (percentages).

3. Results

Data were collected from a total of 35 centers, including 26 (74.3%) university hospitals and 9 (25.7%) Ministry of Health Affiliated Hospitals. Twenty-eight (77.1%) centers have HD, PD, and KTx facilities. Demographic and clinical characteristics of patients are given in Tables 1 and 2.

Among 203 patients (89 girls and 114 boys) diagnosed with COVID-19, one-third (36.9%) were between 10–15 years old and almost two-thirds (60.5%) were between 10–18 years. Only 5.4% of the patients were under 2 years of age (Table 1). Kidney transplant recipients comprised the main group (n = 56, 27.5%) and followed by patients receiving chronic HD (n = 33, 16.3 %), glomerulopathies (n = 31, 15.2%) and those on PD (n = 18, 8.9 %). Half of the patients with glomerulopathies were on a single or combination of conventional and/or biologic immunosuppressives. Other diagnostic groups are listed in Table 1. Almost half (n = 100, 49.3%) of the children had at least one comorbid condition, and 30% of them had multiple comorbidities.

Fifty-six percent of the patients were diagnosed when they applied to the hospital with complaints, either in the same clinic (n = 56, 42.3%) or in another health center (n = 28, 13.7%). Other patients had their diagnosis during PCR screening tests; 62 (30.5%) patients with a history of household contact with an index case were diagnosed via filiation, 18 (8.8%) patients with a routine PCR test before hospitalization for another reason. One hundred and seventy (83.7%) patients were diagnosed as COVID-19 disease by SARS-CoV-2 PCR test positivity, 12 (5.9%) by SARS-CoV-2 immunoglobulin M positivity, 11 (5.4%) by thorax tomography findings compatible with COVID-19 pneumonia and 10 (4.9%) by highly suggestive clinical symptoms like fever, cough or shortness of breath that were not explained by another cause.

Fifty-four (26.6%) children were asymptomatic, and 67 (33%) children presented with mild symptoms. Eighty-two (40.3%) patients were hospitalized and 23 (28%) of them needed ICU stay. The patients were most frequently hospitalized for 3–7 days (35.4%) and 7–14 days (31.7%). Only seven (8.5%) patients required >30 days of hospital stay. More than half of the patients (55%) were not treated, while the remaining patients were mostly given favipiravir (20.7%), steroids (16.3%), and hydroxychloroquine (11.3%). Some of the patients were treated with additional combination regimens of intravenous immunoglobulin (IVIG), low molecular weight heparin (LMWH), or biologic anticytokine therapies. Acute kidney injury developed in 19.5% of the hospitalized patients during the course of the disease. Five patients (2.4%) had the diagnosis of MIS-C. A total of 7 (3.4%) patients died during the study period. Of the patients who died, 3 (42.8%) died due to MIS-C, 2 (28.5%) due to COVID-19 pneumonia, 1 (14.2%) due to post-COVID cardiac arrest after discharge from the hospital, and 1 (14.2%) due to COVID-unrelated reason. Fortunately, 83% of the patients were discharged without any apparent sequelae.
In addition, a total of 108 healthcare staff members, 25 of whom were pediatric nephrologists and 27 of whom were nurses, were infected. Vaccination was available for healthcare staff in the second half of January 2021 and staff infections were all recorded prior to the vaccination era.

4. Discussion
In this one-year retrospective study, starting from the day of the first COVID-19 case detected in Turkey, the characteristics of 203 pediatric nephrology patients diagnosed with COVID-19 were evaluated. More than half of the patients were asymptomatic or mildly symptomatic. Although the hospitalization rate in PN patients was 40.3%, most of the patients were discharged without any sequelae. However, viral transmission to healthcare personnel in prevaccination era was remarkable.

COVID-19 disease is not only a respiratory infection but also a systemic disease that affects multiple organs. Since the SARS CoV-2 virus uses the angiotensin-converting enzyme-2 (ACE2) and transmembrane protease serine type 2 receptors to enter the cell and these molecules are highly expressed in kidney cells, the kidneys are one of the organs most frequently affected by COVID-19 disease. It causes directly parenchymal infection in tubule epithelial cells and podocytes, acute tubular injury, and acute tubular necrosis. The most common signs of renal involvement are increased serum creatinine level, proteinuria, and hematuria. Patients with preexisting kidney disease are at higher risk of developing serious illnesses from COVID-19 [27]. Therefore, it is essential to prevent kidney damage due to COVID-19 and to protect patients with kidney disease from the increased morbidity and mortality risks of COVID-19.

A study evaluating previously healthy patients in the 0–15 age group observed that 18.1% of patients were <1 year of age, 23.4% were 1–5 years, 33.9% were 6–10 years, 24.6% were 11–15 years [1]. In our study, when patients in the 0–15 age range with a known kidney pathology were evaluated, only 3.5% of patients were <1 year of age, 16.9% were 1–5 years, 26.7% were 6–10 years, 52.8% were 11–15
Table 2. Clinical characteristics of patients with COVID-19.

<table>
<thead>
<tr>
<th>All patients with COVID-19, n (%)</th>
<th>203 (100)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Outpatient clinic, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Asymptomatic</td>
<td>54 (26.6)</td>
</tr>
<tr>
<td>Mild symptomatic</td>
<td>67 (33)</td>
</tr>
<tr>
<td><strong>Hospitalized patients, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>59 (29)</td>
</tr>
<tr>
<td>Severe/critical</td>
<td>23 (11.3)</td>
</tr>
<tr>
<td><strong>How to reach a diagnosis, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Filialation</td>
<td>62 (30.5)</td>
</tr>
<tr>
<td>Admitting to hospital with complaints</td>
<td>86 (42.3)</td>
</tr>
<tr>
<td>Routine PCR test prior to hospitalization for another reason</td>
<td>18 (8.8)</td>
</tr>
<tr>
<td>Diagnosis at another center</td>
<td>28 (13.7)</td>
</tr>
<tr>
<td>During a regular visit, screening tests due to family history</td>
<td>9 (4.4)</td>
</tr>
<tr>
<td><strong>Primary method for diagnosing COVID-19, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>SARS CoV-2 PCR test</td>
<td>170 (83.7)</td>
</tr>
<tr>
<td>SARS CoV-2 IgM-IgG</td>
<td>12 (5.9)</td>
</tr>
<tr>
<td>Thorax computer tomography</td>
<td>11 (5.4)</td>
</tr>
<tr>
<td>High clinical suspicion</td>
<td>10 (4.9)</td>
</tr>
<tr>
<td><strong>Treatments, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>No treatment</td>
<td>112 (55)</td>
</tr>
<tr>
<td>Favipiravir</td>
<td>42 (20.7)</td>
</tr>
<tr>
<td>Oseltamivir</td>
<td>5 (2.5)</td>
</tr>
<tr>
<td>Lopinavir-ritonavir</td>
<td>5 (2.5)</td>
</tr>
<tr>
<td>Remdesivir</td>
<td>1 (0.5)</td>
</tr>
<tr>
<td>Antibiotics</td>
<td>18 (8.9)</td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
<td>23 (11.3)</td>
</tr>
<tr>
<td>Steroids</td>
<td>33 (16.3)</td>
</tr>
<tr>
<td>Anakinra</td>
<td>6 (3)</td>
</tr>
<tr>
<td>LMWH</td>
<td>8 (3.9)</td>
</tr>
<tr>
<td>Aspirin</td>
<td>5 (2.5)</td>
</tr>
<tr>
<td>IVIG</td>
<td>13 (6.4)</td>
</tr>
<tr>
<td>Plasmapheresis</td>
<td>2 (1)</td>
</tr>
<tr>
<td><strong>Length of hospital stay, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>(n = 82)</td>
<td></td>
</tr>
<tr>
<td>1–3 days</td>
<td>2 (2.4)</td>
</tr>
<tr>
<td>3–7 days</td>
<td>29 (35.4)</td>
</tr>
<tr>
<td>7–14 days</td>
<td>26 (31.7)</td>
</tr>
<tr>
<td>14–21 days</td>
<td>14 (17)</td>
</tr>
<tr>
<td>21–30 days</td>
<td>4 (4.8)</td>
</tr>
<tr>
<td>30 days</td>
<td>7 (8.5)</td>
</tr>
<tr>
<td><strong>Outcomes, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Acute kidney injury</td>
<td>16 (7.8)</td>
</tr>
<tr>
<td>Patients discharged from ward with no sequelae</td>
<td>56 (27.6)</td>
</tr>
<tr>
<td>Patients discharged from ward with sequelae</td>
<td>1 (0.5)</td>
</tr>
<tr>
<td>Patients currently hospitalized in ward</td>
<td>2 (1)</td>
</tr>
<tr>
<td>Patients discharged from ICU with no sequelae</td>
<td>12 (5.9)</td>
</tr>
<tr>
<td>Patients discharged from ICU with sequelae</td>
<td>3 (1.5)</td>
</tr>
<tr>
<td>Patients currently in ICU</td>
<td>1 (0.5)</td>
</tr>
<tr>
<td>New onset MIS-C and Kawasaki-like MIS-C</td>
<td>5 (2.5)</td>
</tr>
<tr>
<td>Exitus</td>
<td>7 (3.4)</td>
</tr>
</tbody>
</table>

COVID-19: Coronavirus-19 disease; PCR: Polymerase chain reaction; SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2; IgM: Immunoglobulin M; IgG: Immunoglobulin G; LMWH: Low molecular weight heparin; IVIG: Intravenous immunoglobulin; ICU: Intensive care unit; MIS-C: Multisystem inflammatory syndrome-children
years. The reason why the frequency of COVID-19 in the first year of life was less compared to the literature is that our cases have various renal diseases, and the frequency of these pathologies increases with age.

In a study in which pediatric patients followed up with the diagnosis of inflammatory rheumatoid disease were compared with a healthy control group, it was shown that the presence of inflammatory rheumatoid disease increased the risk of symptomatic infection and hospitalization in terms of COVID-19 disease. It was also shown in that study that the risk of symptomatic infection increases with age [28]. In terms of kidney diseases, CKD was reported to be associated with increased risk, severity, and mortality of COVID-19 disease in adults, however, there is limited information on PN patients [15–17]. In a pediatric study from Spain, 18.7% of patients with COVID-19 had a KTx, and 18.7% were receiving chronic HD [29]. According to our data, 27.5% of the infected patients were KTx recipients, 16.3% were undergoing HD, 8.9% were on PD, 15.2% had glomerulopathies and 9.8% had nondialysis dependent CKD (stage I-V). The higher rates in PN patient groups may be due to their compromised immune system and their more frequent exposure to the hospital setting, i.e. in center HD patients. There is limited evidence in children with KTx suggesting not an increased risk of severe COVID-19 disease [30–33]. Evidence from similar adult KTx populations suggests an increased risk of acquiring COVID-19 and an increased risk of severe disease [34–39]. The incidence of COVID-19 was reported to be similar between pediatric KTx recipients and the general pediatric population [30]. In a study from Turkey evaluating 496 pediatric dialysis and KTx patients, the diagnosis of COVID-19 was made in 46 (9.2%) patients; among them, 63% were KTx recipients and 37% were on dialysis. Although the patients were usually asymptomatic or mildly symptomatic, 22 (47.8%) patients were hospitalized. One patient who underwent HD and had serious comorbid diseases died. The mortality rate was 2% in SARS-CoV-2 positive patients and 4.5% among hospitalized ones [40]. In our study, 82 (40.3%) patients were hospitalized for COVID-19. Twenty-three (11.3%) patients were followed up in the ICU. A total of 7 patients died, including 3 patients with MIS-C, 2 with COVID-19 pneumonia, 1 with sudden cardiac arrest at home after discharge, and 1 with COVID-19-unrelated reasons. We observed the hospitalization rate as 40.3% and the mortality rate as 3.4%. These rates are broadly similar in both studies.

In a study from Turkey including 76 pediatric patients without kidney disease who developed MIS-C, 35.5% of the patients were followed in the ICU and one patient died [41]. In another study conducted on 113 children with kidney disease, no MIS-C cases were reported [42]. Similarly, among pediatric dialysis and KTx patients, only two (0.4%) MIS-C cases were detected without any mortality [40]. Discrepant results in small studies may be due to baseline characteristics and comorbid conditions of the patients and highlighted the necessity of large studies to evaluate the role of underlying kidney disease as risk factors for MIS-C.

Unlike adults, most children present clinical symptoms ranging from asymptomatic to mild/moderate illness [5,43–46]. According to our observation, 26.6% of cases were asymptomatic and 33% cases were mildly symptomatic. Similarly, in another study evaluating children with chronic renal pathologies, 18.7% of patients were asymptomatic, and there were fever and/or cough as the symptoms in 50% of patients [29]. This may be related to the differences in pediatric innate immune system compared to adults, being familiar with other coronaviruses, having fewer ACE2 receptors in the nasal mucosa, or having fewer comorbidities such as diabetes and hypertension [44].

Acute kidney injury (AKI) is commonly seen during COVID-19 course, especially in patients with KTx [15,16,45]. Several systematic reviews reported the association of AKI in severe COVID-19 patients with a poorer prognosis. During COVID-19 course, 27% to 52% of adult KTx recipients and 36% of pediatric KTx recipients developed AKI [47–50]. In our study, 19.5% of hospitalized patients developed AKI. The lower rate of AKI in our study may be explained by recruited patient population which included not only transplant or stage 3–5 CKD patients, but also other kidney pathologies with normal basal kidney functions.

There is currently limited evidence to support the efficacy of a specific antiviral and/or immunomodulatory agent for the treatment of COVID-19 in adults, and no evidence in children [51–55]. In Turkey, antiviral therapy has been prescribed according to guidelines published by the Turkish Ministry of Health [56]. In the first months of the pandemic, hydroxychloroquine was used in the treatment of COVID-19 because it was observed that the risk of ICU admissions was decreased with the use of it [57]. However, since it was seen that it did not reduce the risk of hospitalization or mortality rates in later studies, its use in treatment was terminated [58]. In this study, we observed that treatment regimens were highly heterogeneous. Asymptomatic or mildly symptomatic patients were not treated while the remaining patients were mostly given favipiravir and steroids. Some of the patients were treated with additional combination regimens of IVIG, LMWH, or biologic anticytokine therapies. When our special patient group is taken into consideration, it should be kept in mind that drug interactions may occur due to the usage of multiple drugs, and the drug doses should be adjusted.
based on renal function. Additionally, there are no general rules about the management of immunosuppression. Despite an earlier hesitation on continuation/dose reduction of immunosuppression, studies in PN patients suggested that it should be maintained but maybe individually tailored based on disease severity, which was confirmed by an adult expert opinion in KTx [24,59]. In some studies, antimetabolites were typically reduced or discontinued, but calcineurin inhibitors were maintained if the clinic was not severe [24].

We observed that there were 108 infected healthcare staff, accounting for more than half of the COVID-19 positive patients. In a previous study, 204 (4.3%) healthcare staff were found to be positive for COVID-19 among a total of 4073 hospital staff. Attention was drawn to the importance of strict infection control measures to reduce viral transmission, as healthcare workers are at high risk for COVID-19 [60]. However, all these infections were recorded before the vaccination era in healthcare providers. The optimization of vaccination coverage should be highlighted to prevent subsequent infections.

In conclusion, among PN patients, COVID-19 was most commonly seen in patients who underwent KTx and undergoing HD. The combined immunosuppressive therapy and frequent exposure to the hospital setting may increase these patients’ susceptibility. In the study presenting data for the prevaccination period, a mortality rate of 3.4% and staff infections deserve more attention and further strict precautions. We acknowledge that the data on COVID-19 are rapidly evolving, and further studies are needed in pediatric kidney patients.

Acknowledgment/disclaimers/conflict of interest
This manuscript did not receive any specific grant from funding agencies in the public, private, commercial, or not-for profit sectors.
All authors have no conflicts of interest to disclose.

References
Reports 2021; 23 (8): 58. https://doi.org/10.1007/s11926-021-04555-x


